Compare Stocks → The Hidden Anchor Investment of the Elite Revealed (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KALA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$7.06+5.1%$7.00$5.10▼$16.84$19.91M-1.9725,030 shs7,062 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO0.00%+3.20%-4.10%-12.61%-59.32%Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALAKALA BIO4.2979 of 5 stars3.55.00.04.42.50.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALAKALA BIO3.00Buy$16.50133.71% UpsideCurrent Analyst RatingsLatest KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/17/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $18.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00(Data available from 6/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALAKALA BIO$3.89M5.12N/AN/A$2.79 per share2.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALAKALA BIO-$42.20M-$15.15N/AN/AN/AN/A-366.43%-66.41%8/2/2024 (Estimated)Latest KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALAKALA BION/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALAKALA BIO4.924.224.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipKALAKALA BIO13.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKALAKALA BIO432.82 million2.44 millionNot OptionableKALA HeadlinesRecent News About These CompaniesMay 29, 2024 | globenewswire.comKALA BIO to Present at Jefferies Global Healthcare ConferenceMay 28, 2024 | msn.comDenise Austin Recreates Workout Video From ‘30 Years Ago’ in ‘Then and Now’ PostMay 28, 2024 | thesun.co.ukHallmark’s Mamie Laverock ‘on life support’ after five-story fall as When Calls the Heart star’s family is ‘devastated’May 28, 2024 | msn.com‘Sports Illustrated’ Model Molly Sims, 51, Says She Isn’t ‘Trying to Look 20’May 21, 2024 | finance.yahoo.comWall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)May 16, 2024 | whatsonstage.comBluets with Emma D’Arcy, Kayla Meikle and Ben Whishaw – first lookMay 14, 2024 | wtop.comKALA BIO: Q1 Earnings SnapshotMay 14, 2024 | globenewswire.comKALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 11, 2024 | winnipegfreepress.com‘This is a nightmare’: Former Birchwood Terrace residents scramble to find new homesMay 11, 2024 | thehindu.comModi and Naidu can create more job opportunities for youngsters, claims TDP leadersMay 9, 2024 | broadwayworld.comThe Shed's Open Call Program Features Eight New Performance Works by Emerging NYC ArtistsMay 7, 2024 | stltoday.comUniversity City: MaKayla StewartMay 7, 2024 | stltoday.comSt. Joseph’s: Kayla JansenMay 3, 2024 | bbc.comHope Hicks, prominent ex-Trump aide, called to witness standMay 3, 2024 | kmaland.comUsing data to drive change in fertilizer useMay 3, 2024 | cosmopolitan.comYour Favorite Authors Got Together for a New Horror Anthology and Chloe Gong's Excerpt Will Terrify YouMay 2, 2024 | uk.style.yahoo.comI tried $1,485 worth of products from Sephora — here's what I would re-buy (and what I would skip)May 2, 2024 | msn.com'Selling the OC' Is Back for Season 3 — Here's All the Juicy Cast Details You Need to KnowMay 2, 2024 | msn.comMeet the glamorous cast of Selling The OC season 3May 1, 2024 | cronkitenews.azpbs.orgDowntown Phoenix Farmers Market, Phoenix Bioscience Core promote health education at festivalNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsKALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
